Ferring Holding SA, founded in 1950 and headquartered in Switzerland, is a global biopharmaceutical group focused on the research, development, and commercialization of innovative medicines. The company primarily specializes in reproductive health, urology, and gastroenterology, with a strong commitment to improving patient outcomes through advanced therapies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| FERHOL 1.05% 2025-07-09 CHFFerring Holding SA | Switzerland | 2025-07-09 | 1.050 | 0.00 |
| FERHOL 2.70% 2027-04-21 CHFFerring Holding SA | Switzerland | 2027-04-21 | 2.700 | 0.83 |
| FERHOL 3.25% 2031-04-21 CHFFerring Holding SA | Switzerland | 2031-04-21 | 3.250 | 1.37 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Ferring began issuing bonds to support its growth strategy in the early 2000s, and notable issuances include a €300 million bond in 2016 with a coupon rate of 1.875%, aimed at refinancing existing debt. Currently, Ferring bonds yield approximately 3.5%, which is competitive within the biopharmaceutical industry. The company’s bonds often feature unique characteristics, such as callable options, providing Ferring flexibility in managing its capital structure. Recent news highlights Ferring's plans to expand its product pipeline, potentially influencing future bond offerings as they seek to finance new initiatives.